枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐,50-41-9，生产厂家，价格-洛克化工网移动版

返回



基本信息

制备方法及用途

物化性质

安全信息

毒理性

MSDS

结构与计算化学

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐

中文名称：: 枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐

中文别名：: 枸橼酸氯米芬;
N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐;
枸橼酸克罗米芬;
克罗米芬;
克罗米酚柠檬酸盐

英文名称：: Clomifene citrate

英文别名：: clomiphene citrate;
Clomiphene (citrate);
clomiphen citrate;
Clomifene citrate;
fertyl;
mrl41;
omifin;
CLOMID;
dyneric;
mer41;
clomivid;
genozym;
2-(4-[2-Chloro-1,2-diphenylethenyl]phenoxy)-N,N-diethylethanamine,Clomiphene citrate salt;
CLOMPHID;
2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine citrate;
fertivet;
Clomiphene citrate salt

CAS No.：: 50-41-9

分子式：: C₂₆H₂₈ClNO^.C₆H₈O₇

分子量：: 598.08

精确分子量：: 597.21300

PSA：: 144.60000

MDL：: MFCD00058322

EINECS：: 200-035-3

InChI：: The Key: PYTMYKVIJXPNBD-UHFFFAOYSA-N3

危险品标志：

风险术语：: R60;R63

安全术语：: S53;S36/37;S45

分子结构式：

SDS：: 查看

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :: YE0875000

CAS REGISTRY NUMBER :: 50-41-9

LAST UPDATED :: 199709

DATA ITEMS CITED :: 59

MOLECULAR FORMULA :: C26-H28-Cl-N-O.C6-H8-O7

MOLECULAR WEIGHT :: 598.14

WISWESSER LINE NOTATION :: GYR&UYR&R DO2N2&2 &QV1XQVQ&1VQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 5 mg/kg/5D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - visual field changes Endocrine - tumors

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5750 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 530 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 10600 mg/kg/53W-C

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain Skin and Appendages - hair

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 10600 mg/kg/53W-C

TOXIC EFFECTS :: Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Related to Chronic Data - changes in ovarian weight Related to Chronic Data - changes in testicular weight

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2500 ug/kg

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Reproductive - Tumorigenic effects - uterine tumors

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2 mg/kg

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Reproductive - Tumorigenic effects - ovarian tumors

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Parenteral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Reproductive - Tumorigenic effects - uterine tumors

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 43 mg/kg

SEX/DURATION :: male 60 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 35 mg/kg

SEX/DURATION :: female 30 week(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - parturition Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Effects on Newborn - stillbirth

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 15 mg/kg

SEX/DURATION :: female 15 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - eye/ear

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 33 mg/kg

SEX/DURATION :: male 1-26 week(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 150 mg/kg

SEX/DURATION :: male 30 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3 mg/kg

SEX/DURATION :: female 9-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3500 ug/kg

SEX/DURATION :: male 7 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 600 ug/kg

SEX/DURATION :: female 6 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 6 mg/kg

SEX/DURATION :: female 9-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - physical

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 7 mg/kg

SEX/DURATION :: female 1-7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 100 ug/kg

SEX/DURATION :: female 1 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Administration onto the skin

DOSE :: 50 ug/kg

SEX/DURATION :: female 1-5 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 300 ug/kg

SEX/DURATION :: female 1-3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2500 ug/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Maternal Effects - other effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 1800 ug/kg

SEX/DURATION :: female 6 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 448 mg/kg

SEX/DURATION :: male 28 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 448 mg/kg

SEX/DURATION :: male 28 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intracerebral

DOSE :: 5 ug/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2 mg/kg

SEX/DURATION :: female 5 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Effects on Newborn - delayed effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2 mg/kg

SEX/DURATION :: female 5 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2 mg/kg

SEX/DURATION :: female 5 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - delayed effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 625 ug/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 96 mg/kg

SEX/DURATION :: female 9-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3 mg/kg

SEX/DURATION :: female 3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 12 mg/kg

SEX/DURATION :: female 1-3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 5 gm/kg

SEX/DURATION :: female 2 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 100 mg/kg

SEX/DURATION :: female 2-3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 25 mg/kg

SEX/DURATION :: female 5 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1325 mg/kg

SEX/DURATION :: male 53 week(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1325 mg/kg

SEX/DURATION :: female 53 week(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 40 mg/kg

SEX/DURATION :: female 2-5 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 500 mg/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 20 mg/kg

SEX/DURATION :: female 10 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 7500 ug/kg

SEX/DURATION :: female 2 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 30 mg/kg

SEX/DURATION :: female 10-12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 4 mg/kg

SEX/DURATION :: female 2 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 30 mg/kg

SEX/DURATION :: female 10-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 1200 ug/kg

SEX/DURATION :: female 1-24 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2 mg/kg

SEX/DURATION :: female 1 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 700 mg/kg

SEX/DURATION :: male 14 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

MUTATION DATA

TYPE OF TEST :: DNA inhibition

TEST SYSTEM :: Bacteria - Escherichia coli

DOSE/DURATION :: 50 mg/L

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 165,57,1986 *** REVIEWS *** IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 21,551,1979 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 21,551,1979 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,172,1987 TOXICOLOGY REVIEW CLECAP Clinical Endocrinology (Oxford). (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.1- 1972- Volume(issue)/page/year: 4,551,1975

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐 MSDS

模块 1. 化学品
  1.1 产品标识符
    : 克罗米酚柠檬酸盐
    产品名称
  1.2 鉴别的其他方法
    2-(4-[2-Chloro-1,2-diphenylethenyl]phenoxy)-N,N-diethylethanamine
  1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
    仅用于研发。不作为药品、家庭或其它用途。

模块 2. 危险性概述
  2.1 GHS-分类
    生殖毒性 (类别 2)
  2.2 GHS 标记要素，包括预防性的陈述
    象形图
    警示词        警告
    危险申明
    H361        怀疑对生育能力或胎儿造成伤害。
    警告申明
    预防措施
    P201        在使用前获取特别指示。
    P202        在读懂所有安全防范措施之前切勿操作。
    P281        使用所需的个人防护设备。
    事故响应
    P308 + P313        如接触到或有疑虑：求医/ 就诊。
    安全储存
    P405        存放处须加锁。
    废弃处置
    P501        将内容物/ 容器处理到得到批准的废物处理厂。
    只限于专业使用者。
  2.3 其它危害物 - 无

模块 3. 成分/组成信息
  3.1 物质
    : 2-(4-[2-Chloro-1,2-diphenylethenyl]phenoxy)-N,N-diethylethanamine
    别名
    : C26H28ClNO · C6H8O7
    分子式
    : 598.08 g/mol
    分子量
    组分        浓度或浓度范围
    Clomifen dihydrogen citrate
    <=100%
    化学文摘登记号(CAS        50-41-9
    No.)        200-035-3
    EC-编号

模块 4. 急救措施
  4.1 必要的急救措施描述
    一般的建议
    请教医生。向到现场的医生出示此安全技术说明书。
    吸入
    如果吸入,请将患者移到新鲜空气处。如呼吸停止,进行人工呼吸。请教医生。
    皮肤接触
    用肥皂和大量的水冲洗。请教医生。
    眼睛接触
    用水冲洗眼睛作为预防措施。
    食入
    切勿给失去知觉者通过口喂任何东西。用水漱口。请教医生。
  4.2 主要症状和影响，急性和迟发效应
    据我们所知，此化学，物理和毒性性质尚未经完整的研究。, 视力模糊, 长期或频繁接触会导致：, 恶心, 头痛,
    呕吐
  4.3 及时的医疗处理和所需的特殊处理的说明和指示
    无数据资料

模块 5. 消防措施
  5.1 灭火介质
    灭火方法及灭火剂
    用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
  5.2 源于此物质或混合物的特别的危害
    碳氧化物, 氮氧化物, 氯化氢气体
  5.3 给消防员的建议
    如必要的话,戴自给式呼吸器去救火。
  5.4 进一步信息
    无数据资料

模块 6. 泄露应急处理
  6.1 作业人员防护措施、防护装备和应急处置程序
    使用个人防护用品。避免粉尘生成。避免吸入蒸气、烟雾或气体。保证充分的通风。
    人员疏散到安全区域。避免吸入粉尘。
  6.2 环境保护措施
    如能确保安全，可采取措施防止进一步的泄漏或溢出。不要让产品进入下水道。
  6.3 泄漏化学品的收容、清除方法及所使用的处置材料
    收集和处置时不要产生粉尘。扫掉和铲掉。放入合适的封闭的容器中待处理。
  6.4 参考其他部分
    丢弃处理请参阅第13节。

模块 7. 操作处置与储存
  7.1 安全操作的注意事项
    避免接触皮肤和眼睛。避免形成粉尘和气溶胶。
    在有粉尘生成的地方,提供合适的排风设备。一般性的防火保护措施。
  7.2 安全储存的条件,包括任何不兼容性
    贮存在阴凉处。使容器保持密闭，储存在干燥通风处。
  7.3 特定用途
    无数据资料

模块 8. 接触控制和个体防护
  8.1 容许浓度
    最高容许浓度
    没有已知的国家规定的暴露极限。
  8.2 暴露控制
    适当的技术控制
    根据良好的工业卫生和安全规范进行操作。休息前和工作结束时洗手。
    个体防护设备
    眼/面保护
    带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟)
    检测与批准的设备防护眼部。
    皮肤保护
    戴手套取手套在使用前必须受检查。
    请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
    使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
    所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
    身体保护
    防渗透的衣服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
    呼吸系统防护
    如危险性评测显示需要使用空气净化的防毒面具，请使用全面罩式多功能微粒防毒面具N100型（US
    ）或P3型（EN
    143）防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式，则使用全面罩式送风防毒
    面具。呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。

模块 9. 理化特性
  9.1 基本的理化特性的信息
    a) 外观与性状
    形状: 固体
    b) 气味
    无数据资料
    c) 气味阈值
    无数据资料
    d) pH值
    无数据资料
    e) 熔点/凝固点
    无数据资料
    f) 沸点、初沸点和沸程
    无数据资料
    g) 闪点
    无数据资料
    h) 蒸发速率
    无数据资料
    i) 易燃性(固体,气体)
    无数据资料
    j) 高的/低的燃烧性或爆炸性限度无数据资料
    k) 蒸气压
    无数据资料
    l) 蒸汽密度
    无数据资料
    m) 密度/相对密度
    无数据资料
    n) 水溶性
    无数据资料
    o) n-辛醇/水分配系数
    无数据资料
    p) 自燃温度
    无数据资料
    q) 分解温度
    无数据资料
    r) 粘度
    无数据资料

模块 10. 稳定性和反应活性
  10.1 反应性
    无数据资料
  10.2 稳定性
    无数据资料
  10.3 危险反应
    无数据资料
  10.4 应避免的条件
    无数据资料
  10.5 不相容的物质
    强氧化剂
  10.6 危险的分解产物
    其它分解产物 - 无数据资料

模块 11. 毒理学资料
  11.1 毒理学影响的信息
    急性毒性
    半数致死剂量 (LD50) 经口 - 大鼠 - 5,750 mg/kg
    皮肤刺激或腐蚀
    无数据资料
    眼睛刺激或腐蚀
    无数据资料
    呼吸道或皮肤过敏
    无数据资料
    生殖细胞致突变性
    无数据资料
    致癌性
    该产品不是或不包含被IARC, ACGIH, EPA, 和 NTP 列为致癌物的组分
    IARC:
    3 - 第3组：未被分类为对人类致癌 (Clomifen dihydrogen citrate)
    生殖毒性
    婴儿可能出现先天性畸形和畸形的危险
    可疑人类的生殖毒物
    能引起生殖紊乱
    特异性靶器官系统毒性（一次接触）
    无数据资料
    特异性靶器官系统毒性（反复接触）
    无数据资料
    吸入危险
    无数据资料
    潜在的健康影响
    吸入        吸入可能有害。可能引起呼吸道刺激。
    摄入        如服入是有害的。
    皮肤        通过皮肤吸收可能有害。可能引起皮肤刺激。
    眼睛        可能引起眼睛刺激。
    接触后的征兆和症状
    据我们所知，此化学，物理和毒性性质尚未经完整的研究。, 视力模糊, 长期或频繁接触会导致：, 恶心, 头痛,
    呕吐
    附加说明
    化学物质毒性作用登记: YE0875000

模块 12. 生态学资料
  12.1 生态毒性
    无数据资料
  12.2 持久性和降解性
    无数据资料
  12.3 潜在的生物累积性
    无数据资料
  12.4 土壤中的迁移性
    无数据资料
  12.5 PBT 和 vPvB的结果评价
    无数据资料
  12.6 其它不良影响
    无数据资料

模块 13. 废弃处置
  13.1 废物处理方法
    产品
    将剩余的和不可回收的溶液交给有许可证的公司处理。
    联系专业的拥有废弃物处理执照的机构来处理此物质。
    与易燃溶剂相溶或者相混合，在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧
    受污染的容器和包装
    按未用产品处置。

模块 14. 运输信息
  14.1 联合国危险货物编号
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.2 联合国运输名称
    欧洲陆运危规: 非危险货物
    国际海运危规: 非危险货物
    国际空运危规: 非危险货物
  14.3 运输危险类别
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.4 包裹组
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.5 环境危险
    欧洲陆运危规: 否        国际海运危规        国际空运危规: 否
    海洋污染物（是/否）: 否
  14.6 对使用者的特别提醒
    无数据资料

模块 15 - 法规信息
N/A

模块16 - 其他信息
N/A

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐制备方法及用途

制备方法

合成制备方法

用途简介

用途

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐物化性质

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐安全信息

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐毒理性

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐 MSDS

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐分子结构与计算化学数据

计算化学数据

推荐供应商

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐 制备方法及用途

制备方法

合成制备方法

用途简介

用途

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐 物化性质

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐 安全信息

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐 毒理性

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐 MSDS

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐 分子结构与计算化学数据

计算化学数据

推荐供应商

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐制备方法及用途

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐物化性质

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐安全信息

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐毒理性

枸橼酸氯米芬; N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸橼酸盐分子结构与计算化学数据